Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)
Forecasted Federal grant Posted
- Opportunity number
- RFA-DK-28-113
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications expected due
- Award size
- Not on record
Opportunity facts
- Expected posting
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- City/Township Governments
- Other
- Public or Indian Housing Auth.
- Higher Education Inst. (Public)
- Tribal Organizations (Not Federally Recognized)
- Non-501(c)(3) Nonprofits
- Small Businesses
- Tribal Governments (Federally Recognized)
- Special District Governments
- Higher Education Inst. (Private)
- For Profit Organizations
- 501(c)(3) Nonprofits
- Independent School Districts
- State Governments
- County Governments
- Points of contact
-
- Albert Hwa niddk_dem@nih.gov
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health is forecasting a cooperative agreement opportunity under U01 Clinical Trial Not Allowed to fund research using human-relevant New Approach Methodologies (NAMs) on the earliest events that initiate and drive Type 1 Diabetes (T1D). Projects will use human cells and tissues with organoids, microphysiological systems, and other advanced human-relevant models, combined with experimental and computational approaches, to identify and validate early biomarkers and therapeutic targets and to advance strategies that prevent or interrupt disease progression before substantial pancreatic beta cell loss occurs.
Eligibility is broad. Listed applicant types include city, county, state, and tribal governments (federally recognized and not federally recognized), public housing authorities, special district and independent school district governments, public and private higher education institutions, small businesses, for-profit organizations, and 501(c)(3) and non-501(c)(3) nonprofits. Other eligible applicants include federal agencies, U.S. territories or possessions, faith-based or community-based organizations, regional organizations, and non-domestic (foreign) institutions.
Funded projects will join the Human Islet Research Network (HIRN). Awardees will be expected to participate in collaborative activities, share tools and data, coordinate use of scarce human pancreatic tissues, and promote harmonization and interoperability of approaches and datasets where appropriate.
The source does not state award ceilings, floors, expected award counts, period of performance, or place of performance, and it names no incumbent recipient. Parent program 93.KRP (Diabetes, Digestive, Kidney Extramural Research - Research Projects) lists six review elements: scientific merit and significance, technical adequacy of design, investigator competency, facilities and resources, budget necessity, and relevance to program objectives. Parent program 93.855 (Allergy and Infectious Diseases Research) carries the same core review elements.
Forecast synopsis
This NOFO will support research using human-relevant New Approach Methodologies (NAMs) to advance understanding of the earliest events that initiate and drive Type 1 Diabetes (T1D). Projects will use human cells and tissues and innovative experimental and computational approaches-including organoids, microphysiological systems, and other advanced human-relevant models-to investigate cellular and molecular mechanisms involved in T1D initiation and early disease progression. The research is expected to identify and validate early biomarkers and therapeutic targets and advance new strategies to prevent or interrupt disease progression before substantial pancreatic beta cell loss occurs.
Funded projects will become part of the Human Islet Research Network (HIRN), providing a collaborative environment that brings together complementary expertise, technologies, human biological resources, and datasets. Awardees will be expected to participate in collaborative activities, share tools and data, coordinate the use of scarce human pancreatic tissues, and promote harmonization and interoperability of approaches and datasets where appropriate. Through this coordinated research effort, the initiative seeks to overcome barriers that have limited progress by individual laboratories and accelerate the translation of discoveries about early human T1D into biomarkers, therapeutic targets, and ultimately preventive or treatment strategies.
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity